Mechanism of action of fibrates on lipid and lipoprotein metabolism

Circulation

Volumn 98, Issue 19, 1998, Pages 2088-2093

  Staels, Bart ^a   Dallongeville, Jean ^b   Auwerx, Johan ^c   Schoonjans, Kristina ^d   Leitersdorf, Eran ^a   Fruchart, Jean Charles ^a  

^a Unité 325 INSERAI

^b INSTITUT PASTEUR DE LILLE   (France)

^c Prevention and Treatment of Atherosclerosis

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Apolipoproteins; Arteriosclerosis; Fibrates; Hypercholesterolemia; Hyperlipoprote inemia; Lipids; PPAR

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPIDEMIA; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032506273     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.19.2088     Document Type: Article

References (78)

1. Prevention of coronary heart disease: scientific background and new clinical guidelines: recommendations of the European Atherosclerosis Society prepared by International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis. 1992:2:113-156.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
3. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Malkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkilä EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
4. Huttunen J, Manninen V, Manttari M, Koskinen P, Romo M, Tenkanen L, Heinonen O, Frick M. The Helsinki Heart Study: central findings and clinical implications. Ann Med. 1991;23:155-159.
5. Huttunen J, Heinonen O, Manninen V, Koskinen P, Hakulinen T, Teppo L, Manttari M, Frick M. The Helsinki heart study: an 8.5-year safety and mortality follow-up. J Intern Med. 1994;235:31-39.
6. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographie assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
7. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternak A, Taskinen MR. Prevention of the angio-graphic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-2143.
8. Tikkanen M. Fibric acid derivatives. Curr Opin Lipidol. 1992;3:29-33.
9. Zimetbaum P, Frishman W, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol. 1991;31:25-37.
10. Davignon J. Fibrates: a review of important issues and recent findings. Can J Cordial. 1994;10:61B.
11. Caslake M, Packard C, Gaw E, Murray E, Griffin B, Vallance B, Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702-711.
12. Brucken E, Dejager S, Chapman M. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia (published erratum appears in Atherosclerosis. 1993 102:129). Atherosclerosis. 1993;100:91-102.
13. de Graaf J, Hendriks J, Demacker P, Stalenhoef A. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb. 1993:13:712-719.
14. Bard J-M, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C, Brucken E, Douste-Blazy P, Drouin P, Jacotot B, De Gennes JL, Keller U, Fruchan J-C. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism. 1992;41:498-503.
15. Lussier-Cacan S, Bard J-M, Boulet L, Nestruck A, Grothé A-M, Fruchan J-C, Davignon J. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis. 1989;78:167-182.
16. Luc G, Fievet C, Arveiler D, Evans A, Bard J, Cambien F, Fruchart J, Ducimeliere P. Apolipoproteins C-III and E in apo-B and non apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res. 1996:37:508-517.
17. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate, and probucol on plasma lipolytic enzymes in normolipidaemic subjects. Eur J Clin Pharmacol. 1983;23:57-63.
18. Malmendier C, Lontie J-F, Delcroix C, Dubois D, Magot T, De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients: effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989;77: 139-149.
19. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARa and PPARy activators. J Biol Chem. 1997;272:28210-28217.
20. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acylcoenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem. 1995:270:19269-19276.
21. D'Costa MA, Angel A. Inhibition of hormone-stimulated lipolysis by clofibrate: a possible mechanism for its hypolipidemic action. J Clin Invest. 1975:55:138-148.
22. Mann C, Yen F, Grant A, Bihain B. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991:88:2059-2066.
23. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Imest. 1995;96:741-750.
24. 24: Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart J-C, Rubin E, Denefle P, Staels B, Branellec D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. J Clin Invest. 1996:97:2408-2416.
25. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996:37:907-925.
26. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302:93-109.
27. Auboeuf D, Rieusset J, Fajas L, Valuer P, Frering V, Riou JP, Laville M, Staels B, Auwerx J, Vidai H. Tissue distribution and quantification of the expression of the peroxisome proliferator activated receptors and of LXRa mRNAs in human: effect of obesity and NIDDM in adipose tissue. Diabetes. 1997;46:1319-1327.
28. Forman B, Tontonoz P, Chen J, Bran R, Spiegelman B, Evans R. 15-Deoxy-A12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARy. Cell. 1995;83:803-812.
29. Kliewer S, Lenhard J, Willson T, Patel I, Morris D, Lehman J. A prostaglandin J2 metabolite binds pcroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83: 813-819.
30. Kliewer S, Sundseth S, Jones S, Brown P, Wisely G, Koble C, Devchand P, Wahli W, Willson T, Lenhard J, Lehmann J. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Nail AcadSci USA. 1997;94:4318-4323.
31. Forman B, Chen J, Evans R. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sei USA. 1997;94:4312-4317.
32. Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 1996; 384:39-43.
33. Gulick T, Cresci S, Caira T, Moore D, Kelly D. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Nail Acad Sei USA. 1994;91: 11012-11016.
34. Staels B, Vu-Dac N, Kosykh V, Saladin R, Frachart JC, Dallongeville J, Auwerx J. Fibrates down-regulate apolipoprotein C-I1I expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest. 1995;95:705-712.
35. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996:15:5336-5348.
36. Peters JM, Hennuyer N, Staels B, Fruchart J-C, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in PPARα-deficient mice. J Biol Chem. 1997;272:27307-27312.
37. Lamb R, Koch J, Bush S. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim Biophys Ada. 1993;1165:299-305.
38. Maragandakis M, Hankin H. On the mode of action of lipid lowering agents, V: kinetics of the inhibition in vitro of rat acetyl-CoA carboxylase. J Biol Chem. 1971;246:348-354.
39. Malmendier C, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 1985;55:161-169.
40. Mellies M, Stein E, Khoury P, Lamkin G, Glueck C. Effects of fenofibrate on lipids, lipoproteins and apolipoproteins in 33 subjects with primary hypercholesterolaemia. Atherosclerosis. 1987;63:57-64.
41. Vu-Dac N, Schoonjans K, Laine B, Fruchart J, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269: 31012-31018.
42. Bradford R, Goldberg A, Schonfeld G, Knopp R. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis. 1992;92:31-40.
43. Dachet C, Cavalerro E, Martin C, Girardot G, Jacotot B. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis. 1995;113:1-9.
44. Simo I, Yakichuk J, Ooi T. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 1993;100:55-64.
45. Bhatnagar D, Durrington P, Mackncss M, Arrol S, Winocour P, Prais H. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis. 1992;92:49-57.
46. Nigon F, Lesnik P, Rouis M, Chapman M. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.
47. Larsen M, Illingwonh D, O'Malley J. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis. 1994; 106:235-240.
48. Zhao S, Smelt A, Lernen J, Vroom T, van der Laarse A, van't Hooft F. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. Am J Med. 1994;96:49-56.
49. Zelis R, Amsterdam A, Spann JJ, Mason D. Type IV hyperlipoproteinemia: clofibrate without dietary therapy. JAMA. 1972;222:326-328.
50. Wolf H. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Drug Exp Clin Res. 1994:20:109-113.
51. Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D, Mannarino E, Ventura A. Efficacy of ciprofibrate in primary type II and IV hypcrlipidemia: the Italian multicenter study. Clin Ther. 1990:12:482-488.
52. Hokanson J, Austin M, Zambon A, Brunzcll J. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:427-434.
53. Lupien P, Brun D, Gagne C, Moorjani S, Bielman P, Julien P. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Can J Cardiol. 1991;7:27-33.
54. Goldberg R, La-Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulindependent diabetes mellitus. Am J Cardiol. 1990;66:16B-21B.
55. Pasternak R, Brown L, Stone P, Silverman D, Gibson C, Sacks F. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized, placebo-controlled trial: Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med. 1996;125:529-540.
56. Tilly-Kiesi M, Tikkanen M. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Intern Med. 1991;229:427-434.
57. Franceschini G, Lovati M, Manzoni C, Michelagnoli S, Pazzucconi F, Gianfranceschi G, Vecchio G, Sinon C. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis. 1995;114:61-71.
58. Simpson H, Williamson C, Olivecrona T, Pringle S, Maclean J, Lorimer A, Bonnefous F, Bogaievsky Y, Packard C, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 1990; 85:193-202.
59. Niort G, Cassader M, Gambiano R, Pagano G. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab. 1992:18:221-228.
60. Sweany A, Sfiapiro D, Tate A, Goldberg R, Stein E. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with noninsulin-dependent diabetes mellitus: NIDDM Study Group. Clin Ther. 1995:17:186-203.
61. Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen M. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993:36:161-169.
62. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995;44:212-217.
63. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen M. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care. 1993;16:584-592:
64. Cavaliere E, Piolot A, Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabetes Metab. 1995:21:118-120.
65. Sgro C, Escousse A. Side effects of fibrates (except liver and muscle). Therapie. 1991;46:351-354.
66. Roberts W. Safety of fenofibrate: US and worldwide experience. Cardiology. 1989;76:169-179.
67. Newman T, Hulley S. Carcinogenicity of lipid-lowering drugs. JAAfA. 1996:275:55-60.
68. Gariot P, Barrat E, Mejean L, Pointel J, Drouin P, Debry G. Fenofibrate and human liver: lack of proliferation of peroxisomes. Arch Toxicol. 1983:53:151-163.
69. Angelin B, Einarsson K, Leijd B. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinemia. Eur J Clin Invest. 1984:14:73-78.
70. Blum A, Seligmann H, Livneh A, Ezra D. Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. IsrJMedSci. 1992:28:47-49.
71. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978; 40:1069-1118.
72. Oliver MF, Heady JA, Morris JN, Cooper J. WHO cooperative trial on the primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984:2:600-604.
73. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J. 1971:4:775-784.
74. Trial of clofibrate in the treatment of ischaemic heart disease: five year study by a group of physicians of the Newcastle upon Tyne region. Br Med J. 1971:4:767-775.
75. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience of the Helsinki Heart Study. Circulation. 1995:92:1779-1785.
76. Bloomfield Rubins H, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer FJ, Schectman G, Wittes JT. Rationale and design of the department of veterans affairs high-density lipoprotein cholesterol intervention trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71: 45-52.
77. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flieh M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A, Palant A, Pelled B, Rabinowitz B, Reisin L, Roguin N, Rosenfeld T, Schlesinger Z, Sclarovsky S, Sherf L, Tzivoni D, Zahavi I, Zion M, Brunner D. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993; 71:909-915.
78. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization: the DAIS Project Group. Diabetologia. 1996:39:1655-1661.